Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): Report of the EORTC randomized phase 3 trial 58951

Blood

Volumn 116, Issue 1, 2010, Pages 36-44

  De Moerloose, Barbara ^a   Suciu, Stefan ^b   Bertrand, Yves ^c   Mazingue, Françoise ^d   Robert, Alain ^e   Uyttebroeck, Anne ^f   Yakouben, Karima ^g   Ferster, Alice ^h   Margueritte, Geneviève ⁱ   Lutz, Patrick ^j   Munzer, Martine ^k   Sirvent, Nicolas ^l   Norton, Lucilia ^m   Boutard, Patrick ⁿ   Plantaz, Dominique ^o   Millot, Frederic ^p   Philippet, Pierre ^q   Baila, Liliana ^b   Benoit, Yves ^a   Otten, Jacques ^r  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b EORTC DATA CENTER   (Belgium)

^c HÔPITAL DEBROUSSE   (France)

^d CHR   (France)

^e HÔPITAL DES ENFANTS   (France)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g HÔPITAL ROBERT DEBRÉ   (France)

^h HUDE   (Belgium)

ⁱ Department of Vascular and Thoracic Surgery Arnaud   (France)

^j Department of Hematology ^*  (France)

^k AMERICAN HOSPITAL OF PARIS   (France)

^l UNIVERSITY HOSPITAL OF NICE   (France)

^m HOSPITAL DE SÃO JOÃO   (Portugal)

ⁿ CAEN UNIVERSITY HOSPITAL   (France)

^o CHU La Tronche and University   (France)

^p University of Poitiers   (France)

^q CHC Esperance   (Belgium)

^r UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; VINCRISTINE; ANTINEOPLASTIC AGENT; CORTICOSTEROID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE PANCREATITIS; ARTICLE; BONE NECROSIS; CANCER COMBINATION CHEMOTHERAPY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; CHEMICALLY INDUCED DISORDER; INFANT; MORTALITY; MULTICENTER STUDY; PRESCHOOL CHILD; SURVIVAL; SURVIVAL RATE; TOXIC HEPATITIS; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DEXAMETHASONE; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; INFANT; LYMPHOMA, NON-HODGKIN; MALE; OSTEONECROSIS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISOLONE; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE;

EID: 77955977728     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-10-247965     Document Type: Article

References (23)

1. Hale JP, Lilleyman JS. Importance of 6-mercaptopurine dose in lymphoblastic leukaemia. Arch Dis Child. 1991;66(4):462-466.
2. Sallan SE, Gelber RD, Kimball V, Donnelly M, Cohen HJ. More is better! Update of Dana-Farber Cancer Institute/Children's Hospital childhood acute lymphoblastic leukemia trials. Haematol Blood Transfus. 1990;33:459-466.
3. Chessells JM, Bailey C, Richards SM. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia. Lancet. 1995;345(8943):143-148.
4. Holland JF, Glidewell O. Chemotherapy of acute lymphocytic leukemia of childhood. Cancer. 1972;30(6):1480-1487.
5. Bleyer WA, Sather HN, Nickerson HJ, et al. Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in lowrisk childhood acute lymphoblastic leukemia: a report of the CCG-161 study by the Childrens Cancer Study Group. J Clin Oncol. 1991;9(6):1012-1021.
6. Childhood ALL Collaborative Group. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12.000 randomised children. Lancet. 1996;347(9018):1783-1788.
7. Veerman AJ, Hählen K, Kamps WA, et al. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol. 1996;14(3):911-918. (Pubitemid 126425570)
8. Riehm H, Gadner H, Henze G, et al. Results and significance of six randomized trials in four consecutive ALL-BFM trials. Haematol Blood Transfus. 1990;33:439-450.
9. Conter V, Valsecchi MG, Silvestri D, et al. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. Lancet. 2007;369(9556):123-131. (Pubitemid 46073131)
10. Vilmer E, Suciu S, Ferster A, et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Leukemia. 2000;14(12):2257-2266. (Pubitemid 32042266)
11. Cavé H, Van Der Werff Ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. New Engl J Med. 1998;339(9):591-598. (Pubitemid 28385656)
12. Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol. 2008;9(3):257-268.
13. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207-214.
14. Kalbfleisch JD, Prentice RL. The Clinical Analysis of Failure Time Date. 2nd ed. Hoboken NJ: Wiley InterScience; 2002.
15. Jones B, Freeman AI, Shuster JJ, et al. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol. 1991;19(4):269-275.
16. Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2003;101(10):3809-3817.
17. Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TO. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol. 2005;129(6):734-745. (Pubitemid 40904523)
18. Arico M, Valsecchi MG, Rizzari C, et al. Long-term results of the AIEOP-ALL-95 trial for childhood acute lymphoblastic leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster- based chemotherapy. J Clin Oncol. 2008;26(2):283-289.
19. Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE. Prognostic importance of 6-mercaptopurine therapy in acute lymphoblastic leukemia. Blood. 1999;93(9):2817-2823. (Pubitemid 29200771)
20. Te Poele E, de Bont E, Marike Boezen H, et al. Dexamethasone in the maintenance phase of acute lymphoblastic leukaemia treatment: is the risk of lethal infections too high? Eur J Cancer. 2007;43(17):2532-2536. (Pubitemid 350103545)
21. Silverman LB, Declerck L, Gelber RD, et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia. 2000;14(12):2247-2256.
22. Hanif I, Mahmoud H, Pui CH. Avascular femoral head necrosis in pediatric cancer patients. Med Pediatr Oncol. 1993;21(9):655-660.
23. De Moerloose B, Suciu S, Bertrand Y, et al. Improved outcome with pulses of vincristine (VCR) and steroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL): final report of the EORTC randomized phase IIII trial 58951 [abstract]. Blood. 2008;112(11):(Abstract) 10-11.